GUTS
Fractyl Health, Inc.
$0.91
+0.11 (+13.75%)
At close · Jul 15
Going-concern doubt
— flagged May 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, substantial doubt exists about the Company's ability to continue as a going concern within twelve months from the issuance date of this Quarterly Report on Form 10-Q.”View the 10-Q filed May 12, 2026
Market Cap
$144.37M
Shares
158,648,963
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2025
Net Income
-$140.95M
-105.2%
FY2025
Gross Margin
46.24%
+10.4pp
FY2024
Operating Margin
-100570.97%
-58207.6pp
FY2024
Diluted EPS
-$1.86
-14.8%
FY2025
Operating Cash Flow
-$90.33M
-37.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| — | $0 | $93K | $120K | |
| — | $0 | $50K | $77K | |
| — | — | $43K | $43K | |
| — | — | 46.24% | 35.83% | |
| $70.7M | $74.54M | $70.47M | $38.04M | |
| $22.18M | $22.28M | $23.1M | $12.84M | |
| $92.88M | $96.82M | $93.57M | $50.88M | |
| -$92.88M | -$96.82M | -$93.53M | -$50.84M | |
| — | — | -100570.97% | -42363.33% | |
| $1.63M | $1.54M | $4.15M | $1.26M | |
| -$15.12M | -$44.14M | $24.84M | -$26.26M | |
| — | $0 | $0 | $0 | |
| -$108M | -$140.95M | -$68.69M | -$77.09M | |
| — | — | -73864.52% | -64242.5% | |
| — | -$140.95M | -$70.43M | -$94.27M | |
| USD/shares | — | -$1.86 | -$1.62 | -$45.29 |
| USD/shares | — | -$1.86 | -$1.62 | -$45.29 |
| shares | — | 75.82M | 43.54M | 2.08M |
| shares | — | 75.82M | 43.54M | 2.08M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.54×
EV/EBIT
—
Biotechnology median 25.59×
P/E (TTM)
—
Biotechnology median 7.55×